NASDAQ:KINKindred Biosciences Stock Price, Forecast & News

Kindred Biosciences' stock was trading at $8.09 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, KIN shares have decreased by 36.7% and is now trading at $5.12. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kindred Biosciences.

Kindred Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Kindred Biosciences.

Kindred Biosciences Inc (NASDAQ:KIN) issued its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($0.45) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.41) by $0.04. The biopharmaceutical company earned $0.60 million during the quarter, compared to analyst estimates of $1.75 million. Kindred Biosciences had a negative net margin of 1,567.56% and a negative return on equity of 72.77%. View Kindred Biosciences' earnings history.

6 equities research analysts have issued 12 month price objectives for Kindred Biosciences' stock. Their forecasts range from $8.50 to $13.00. On average, they anticipate Kindred Biosciences' stock price to reach $10.88 in the next year. This suggests a possible upside of 112.4% from the stock's current price. View analysts' price targets for Kindred Biosciences.

News stories about KIN stock have trended very negative on Tuesday, according to InfoTrie. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Kindred Biosciences earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutKindred Biosciences.

Kindred Biosciences saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 383,500 shares, a drop of 12.3% from the April 30th total of 437,100 shares. Based on an average daily volume of 220,200 shares, the short-interest ratio is presently 1.7 days. Currently, 1.0% of the shares of the stock are short sold. View Kindred Biosciences' Current Options Chain.

Some companies that are related to Kindred Biosciences include Collegium Pharmaceutical (COLL), Cara Therapeutics (CARA), Kura Oncology (KURA), Kadmon (KDMN), Molecular Templates (MTEM), ZIOPHARM Oncology (ZIOP), Eagle Pharmaceuticals (EGRX), Retrophin (RTRX), Kala Pharmaceuticals (KALA), Homology Medicines (FIXX), Nabriva Therapeutics (NBRV), Ardelyx (ARDX), Akero Therapeutics (AKRO), Assembly Biosciences (ASMB) and G1 Therapeutics (GTHX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kindred Biosciences investors own include CorMedix (CRMD), bluebird bio (BLUE), Amicus Therapeutics (FOLD), Inovio Pharmaceuticals (INO), Opko Health (OPK), Progenics Pharmaceuticals (PGNX), Rigel Pharmaceuticals (RIGL), Teva Pharmaceutical Industries (TEVA), TherapeuticsMD (TXMD) and Cara Therapeutics (CARA).

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

Kindred Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.27%), Morgan Stanley (4.41%), Granahan Investment Management Inc. MA (2.34%), State Street Corp (1.76%), Geode Capital Management LLC (1.37%) and Assenagon Asset Management S.A. (0.74%). Company insiders that own Kindred Biosciences stock include Park West Asset Management Llc, Raymond Townsend and Richard Chin. View institutional ownership trends for Kindred Biosciences.

KIN stock was sold by a variety of institutional investors in the last quarter, including Healthcare of Ontario Pension Plan Trust Fund, Parametric Portfolio Associates LLC, UBS Group AG, WINTON GROUP Ltd, Morgan Stanley, State Street Corp, Wells Fargo & Company MN, and AQR Capital Management LLC. View insider buying and selling activity for Kindred Biosciences.

KIN stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Granahan Investment Management Inc. MA, Geode Capital Management LLC, Cambridge Investment Research Advisors Inc., Deutsche Bank AG, New York State Common Retirement Fund, Bank of New York Mellon Corp, and Nuveen Asset Management LLC. View insider buying and selling activity for Kindred Biosciences.

Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of KIN stock can currently be purchased for approximately $5.12.

Kindred Biosciences has a market capitalization of $201.16 million and generates $4.26 million in revenue each year. The biopharmaceutical company earns $-61,390,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. Kindred Biosciences employs 146 workers across the globe.

The official website for Kindred Biosciences is kindredbio.com.

Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]